Table 2.
Independent* relation of any CVD, any coronary event, AMI, any cerebrovascular event, stroke, any peripheral event, ulcer/gangrene, and non-advanced and advanced DR with eGFR and albuminuria categories grouped into AKDN risk category 1 and the corresponding KDIGO risk category moderate
| eGFR and albuminuria category | G1-A2 | G2-A2 | G3a-A1 | ||
|---|---|---|---|---|---|
|
Complication |
OR |
OR (95 % CI) |
P
|
OR (95 % CI) |
P
|
|
Any CVD |
1.0 |
1.273 (1.038-1.562) |
0.020 |
1.595 (1.264-2.012) |
<0.0001 |
|
Any coronary event |
1.0 |
1.293 (1.011 1.653) |
0.040 |
1.883 (1.431 2.477) |
<0.0001 |
|
AMI |
1.0 |
1.294 (0.974-1.718) |
0.075 |
1.907 (1.390-2.614) |
<0.0001 |
|
Any cerebrovascular event |
1.0 |
1.483 (1.080-2.036) |
0.015 |
1.641 (1.147-2.349) |
0.007 |
|
Stroke |
1.0 |
1.708 (1.048-2.783) |
0.032 |
1.587 (0.916-2.748) |
0.099 |
|
Any peripheral event |
1.0 |
1.409 (0.988 2.009) |
0.058 |
2.005 (1.359 2.959) |
<0.0001 |
|
Ulcer/gangrene |
– |
– |
– |
– |
– |
|
Non-advanced DR |
1.0 |
0.994 (0.779-1.267) |
0.961 |
0.771 (0.584 1.017) |
0.065 |
| Advanced DR | 1.0 | 1.020 (0.784-1.328) | 0.883 | 0.647 (0.474 0.884) | 0.006 |
*Confounders: age, gender, smoking habits, diabetes duration, HbA1c, anti-hyperglycemic treatment, triglycerides, HDL cholesterol, dyslipidemia, and hypertension.
CVD, cardiovascular disease; AMI, acute myocardial infarction; DR, diabetic retinopathy; eGFR, estimated glomerular filtration rate; KDIGO, kidney disease: improving global outcomes; OR, odd ratio; CI, confidence interval.
G1-A2: eGFR ≥90 ml/min/1.73 m2 with microalbuminuria (reference category); G2-A2: eGFR 60-89 ml/min/1.73 m2 with microalbuminuria; G3a-A1: eGFR 45-59 ml/min/1.73 m2 with normoalbuminuria.